Literature DB >> 24468776

Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.

Fernando César Bizerra1, Cristina Jimenez-Ortigosa, Ana Carolina R Souza, Giovanni Luis Breda, Flávio Queiroz-Telles, David S Perlin, Arnaldo L Colombo.   

Abstract

We identified a case of breakthrough candidemia in a 25-year-old patient receiving micafungin prophylaxis (50 mg/day). Five Candida glabrata isolates were obtained from blood cultures and were classified as multidrug-resistant isolates, since all of them exhibited high MICs for echinocandin and azole drugs. A mutation (S663F) in hot spot 1 of the FKS2 gene was found in all five isolates. This mutation yielded a 1,3-β-D-glucan synthase enzyme with highly reduced sensitivities to echinocandin drugs.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24468776      PMCID： PMC4023795          DOI： 10.1128/AAC.02189-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

2.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

3.  Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.

Authors:  James S Lewis; Nathan P Wiederhold; Brian L Wickes; Thomas F Patterson; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

4.  Novel FKS mutations associated with echinocandin resistance in Candida species.

Authors:  Guillermo Garcia-Effron; Daniel Joseph Chua; Jon Rupert Tomada; Joseph DiPersio; David S Perlin; Mahmoud Ghannoum; Hector Bonilla
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

5.  Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.

Authors:  Mariana Castanheira; Leah N Woosley; Daniel J Diekema; Shawn A Messer; Ronald N Jones; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

6.  FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.

Authors:  Alicia J Zimbeck; Naureen Iqbal; Angela M Ahlquist; Monica M Farley; Lee H Harrison; Tom Chiller; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

7.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.

Authors:  Guillermo Garcia-Effron; Dimitrios P Kontoyiannis; Russell E Lewis; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-09-15       Impact factor: 5.191

9.  Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.

Authors:  Guillermo Garcia-Effron; Samuel Lee; Steven Park; John D Cleary; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

10.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2009-03-01       Impact factor: 9.079
View more
  25 in total

Review 1.  Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.

Authors:  David S Perlin
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 2.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors:  Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

3.  Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar.

Authors:  Saad J Taj-Aldeen; Husam Salah; Winder B Perez; Muna Almaslamani; Mary Motyl; Atqah AbdulWahab; Kelley R Healey; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.

Authors:  Vladimír Hrabovský; Victoria Takáčová; Eva Schréterová; Lydia Pastvová; Zuzana Hrabovská; Katarina Čurová; Leonard Siegfried
Journal:  Folia Microbiol (Praha)       Date:  2017-03-30       Impact factor: 2.099

5.  Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.

Authors:  Sébastien Bailly; Olivier Leroy; Philippe Montravers; Jean-Michel Constantin; Hervé Dupont; Didier Guillemot; Olivier Lortholary; Jean-Paul Mira; Pierre-François Perrigault; Jean-Pierre Gangneux; Elie Azoulay; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2015-09-14       Impact factor: 17.440

6.  Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital.

Authors:  Muneyoshi Kimura; Hideki Araoka; Hisashi Yamamoto; Yuki Asano-Mori; Shigeki Nakamura; Satoshi Yamagoe; Hideaki Ohno; Yoshitsugu Miyazaki; Masahiro Abe; Mitsuhiro Yuasa; Daisuke Kaji; Kosei Kageyama; Aya Nishida; Kazuya Ishiwata; Shinsuke Takagi; Go Yamamoto; Naoyuki Uchida; Koji Izutsu; Atsushi Wake; Shuichi Taniguchi; Akiko Yoneyama
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 7.  Mechanisms of echinocandin antifungal drug resistance.

Authors:  David S Perlin
Journal:  Ann N Y Acad Sci       Date:  2015-07-17       Impact factor: 5.691

8.  Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.

Authors:  Cau D Pham; Naureen Iqbal; Carol B Bolden; Randall J Kuykendall; Lee H Harrison; Monica M Farley; William Schaffner; Zintars G Beldavs; Tom M Chiller; Benjamin J Park; Angela A Cleveland; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

9.  Profiling of PDR1 and MSH2 in Candida glabrata Bloodstream Isolates from a Multicenter Study in China.

Authors:  Xin Hou; Meng Xiao; He Wang; Shu-Ying Yu; Ge Zhang; Yanan Zhao; Ying-Chun Xu
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

10.  Set of classical PCRs for detection of mutations in Candida glabrata FKS genes linked with echinocandin resistance.

Authors:  Catiana Dudiuk; Soledad Gamarra; Florencia Leonardeli; Cristina Jimenez-Ortigosa; Roxana G Vitale; Javier Afeltra; David S Perlin; Guillermo Garcia-Effron
Journal:  J Clin Microbiol       Date:  2014-05-14       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.